Rogaine launched the 2% minoxidil solution in 1988 and the foam formulation in 2007. The active ingredient (minoxidil) is identical in both, but the formulations have meaningfully different characteristics in vehicle composition, propylene glycol content, and application experience that translate into different effectiveness profiles for different users.

The solution contains 50% alcohol and propylene glycol as primary vehicles. Propylene glycol is the major cause of scalp irritation reported by minoxidil users (estimated 6–8% of users). The foam formulation eliminates propylene glycol, substituting fatty alcohols that produce less irritation. However, foam pharmacokinetic studies show somewhat lower follicular minoxidil concentrations compared to the solution at equivalent applied doses, likely related to differences in skin penetration.

Practical guidance: for users who tolerate the solution without irritation, it may produce marginally better hair density outcomes due to better penetration. For users who experience scalp irritation, dandruff-like flaking, or allergic contact dermatitis from the solution, the foam typically resolves these issues without sacrificing meaningful efficacy. Many specialists now default to recommending foam given the irritation rate, with switching to solution reserved for users who don't respond adequately to foam.